AL 8697

Research use only, not for human use.

AL 8697 is a selective p38α MAPK inhibitor (IC50 = 6 nM) with 14-fold selectivity over p38β (IC50 = 82 nM) and 300-fold selectivity over a panel of 91 kinases. AL 8697 has anti-inflammatory activity.

AL 8697 is a selective p38α MAPK inhibitor (IC50 = 6 nM) with 14-fold selectivity over p38β (IC50 = 82 nM) and 300-fold selectivity over a panel of 91 kinases. AL 8697 has anti-inflammatory activity.(In Vivo):In male Wistar rats, AL 8697 (1, 3, 10, 30 mg/kg; p.o.) decreases the oedema in right and left paws in a dose-dependent manner thereby causing a larger improvement in the contralateral un-injected paw.

——

AL 8697 (1-30 mg/kg; p.o.; once daily for 10 days) dose-dependently decreases the oedema in right and left paws. Animal Model:Male Wistar rats Dosage:1, 3, 10, 30 mg/kg Administration:Oral gavage; once daily for 10 days Result:Dose-dependently decreased the oedema in right and left paws, causing a larger improvement in the contralateral un-injected paw.

——

MAPK/ERK Signaling

p38 MAPK

HBV

——

——

1057394-06-5

402.421

C21H21F3N4O

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (248.50 mM)

Cc1c(F)cc(cc1-c1c(F)cn2c(nnc2c1F)C(C)(C)C)C(=O)NC1CC1

——

(-20℃)

With Ice Pack

≥ 2 years